Lennox-Gastaut Syndrome
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE), which commonly begins in early childhood and is characterized by frequent seizures of multiple different types, particularly tonic (stiffening) and atonic (drop) seizures, neurodevelopmental delays, and characteristic electroencephalogram (EEG) abnormalities. LGS may evolve from other epilepsy syndromes, most commonly from infantile spasms.
Key Points
Seizures and safety
There is increased risk of injury from falls during seizures,
especially atonic (drop) seizures. Many individuals with LGS may benefit from a
seizure helmet for head protection. See Safety Precautions for Children with Seizures.
Sudden unexpected death in epilepsy
There is an increased risk of sudden unexpected death in epilepsy
(SUDEP). Adherence to antiseizure medications (ASMs) is essential for decreasing
the risk of SUDEP, and the use of seizure alert devices may be beneficial. See
SUDEP (Sudden Death with Epilepsy) and Danny Did Foundation.
Aspiration pneumonia
Mobility impairment
Individuals with LGS often have challenges with balance, muscle
coordination, and mobility, which can include dysphagia (difficulty swallowing).
Assistive mobility (walker, wheelchair) and eating devices (feeding tube,
gastrostomy tube) may be indicated in some individuals. See Feeding Tubes & Gastrostomies in Children and Wheelchairs and Adapted Strollers.
Early screening
Development delay and learning and behavior problems are common.
Early Developmental Screening and referral to developmental therapies are essential for
pediatric patients with this syndrome. Also see Evaluation of Developmental Delay.
Early treatment
Treatment of epilepsy with antiseizure medications (ASMs) is the
mainstay of LGS management. Seizures are typically refractory to multiple
medications, and non-pharmacological interventions, including diet therapy,
neurostimulation devices, and/or epilepsy surgery, may be indicated.
Early referral to pediatric neurology
Children with LGS should typically be under the care of a
pediatric neurologist with expertise in seizures. If possible, a pediatric
epileptologist is preferred. If LGS is suspected by a primary care provider,
early referral to a pediatric neurologist is highly recommended.
Practice Guidelines
Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A.
Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations.
Front Neurol.
2017;8:505.
PubMed abstract / Full Text
Diagnosis
LGS usually appears in preschool-aged children. It typically takes time for all its features to emerge, making it challenging to accurately diagnose this syndrome in children under 3 years of age.
The diagnosis of LGS is based on a triad of clinical features: [Asadi-Pooya: 2018]
- Multiple seizure types with seizure onset in early childhood
- Characteristic EEG abnormalities
- Developmental delay, intellectual disability
Presentations
- Tonic seizures – body stiffening, often occur during sleep
- Atypical absence seizures – staring, can have eyelid fluttering, chewing movements, longer duration than typical absence seizures
- Atonic seizures – “drop” seizures, cause sudden loss of body tone, often result in falls
- Myoclonic seizures – rapid jerking movements of one or more extremities, head/shoulders, can occur in isolation or clusters
- Generalized tonic-clonic seizures – “convulsive” seizure, full body stiffening followed by rhythmic non-suppressible jerking movements, can be associated with irregular breathing, apnea, cyanosis
- Focal seizures – can have variable presentation, eye/head deviation in 1 direction, 1 extremity and/or 1 side of body stiff, shaking, or both. Can have normal or impaired awareness.
Diagnostic Criteria and Classifications
LGS diagnosis is characterized by a triad of clinical features: [Asadi-Pooya: 2018] [Nelson: 2023]
- Multiple seizure types with seizure onset prior to 18 years, often occurring
in early childhood
- Onset of seizures peaks between 3-5 years of age and can evolve from different epilepsy syndromes, such as infantile epileptic spasms syndrome.
- Primary seizure types include tonic (primarily occurring at night), atonic and atypical absence. Other seizure types may include generalized-tonic clonic, myoclonic, and focal impaired awareness.
- Abnormal EEG findings
- Characteristic interictal (in between seizures) of diffuse slow spike-wave complexes ≤2.5 hz.
- Additional EEG features may include generalized paroxysmal fast activity (GPFA) during non-REM sleep.
- Developmental delay, intellectual disability
- These features may not necessarily be present at seizure onset and may develop over time.
Diagnostic Testing and Screening
Labs
No specific lab test is diagnostic for LGS. However, labs may help assess for potential etiologies (e.g., metabolic or infectious disorders).
Lab monitoring may be indicated in patients taking specific medications (i.e., valproic acid, cannabidiol, felbamate) to assess blood cell counts and liver function and ensure medication levels are within therapeutic range.
Imaging
- Electroencephalogram (EEG) study that captures wakefulness and
sleep
- Slow spike-wave complexes ≤2.5hz
- Generalized paroxysmal fast activity (GPFA) during non-REM sleep
- Magnetic resonance imaging (MRI) – to assess for underlying structural abnormalities (cortical malformations, tumor, stigmata of certain disorders, such as tuberous sclerosis complex)
Genetic Testing
Emerging advances in next-generation sequencing have discovered LGS may be a heterogenous genetic disorder. [Zhou: 2018]
Genetic testing options include a targeted multigene epilepsy panel or whole exome sequencing. Early genetic testing should be considered in patients with LGS of unknown etiology.
Genetics
Incidence and Prevalence
Differential Diagnosis
- Myoclonic atonic epilepsy (MAE) – also known as Doose syndrome
- The predominant seizure types include myoclonic and atonic seizures. Tonic seizures are rare, which is a key feature that distinguishes this syndrome from LGS.
- Dravet syndrome
- Age of seizure onset is earlier than LGS, often <1 year of age.
- Temperature-sensitive/febrile seizures are a characteristic feature. Seizures are often prolonged (status epilepticus) and involve one side of the body (hemiclonic).
- The majority of patients with Dravet syndrome have a mutation in the SCN1A gene, which impacts sodium channel function in the brain.
- Infantile epileptic spasms syndrome (IESS) – formerly known as West
syndrome
- Infantile spasms are clusters of sudden, repeated, uncontrolled movements that resemble body crunching, head bobbing, and/or exaggerated startle.
- Onset peaks between 4-9 months of age but can occur anytime between 2-12 months of age.
- The characteristic brain wave pattern is called hypsarrhythmia.
- Many, but not all, individuals with infantile spasms will develop other seizure types, including LGS.
Comorbid Conditions
Prognosis
LGS is a lifelong neurodevelopmental disorder with epilepsy that is often drug-resistant and requires multiple antiseizure medications. Individuals with LGS often live until their adult years but typically cannot live independently and require assistance with activities of daily living. Individuals with LGS can have varying degrees of intellectual and behavioral disabilities, which often range on the severe end of the spectrum.Treatment and Management
Neurology
Antiseizure Medications
Multiple antiseizure medications (ASMs) are often needed due to the drug-resistant nature of epilepsy in LGS. Patient ASMs should be reviewed regularly to assess potential drug-drug interactions and perform monitoring labs as recommended.
A custom seizure action plan outlining when to administer seizure rescue medication should be addressed and updated annually. [Patel: 2022] [Gidal: 2022].
There are a number of FDA-approved ASMs specifically for the treatment of LGS. Most individuals will require multiple ASMs as well as non-pharmacologic epilepsy treatments during their lifespan.
Valproic acid (Depakote) is considered the first-line treatment for seizures in patients with LGS.
Additional FDA-approved ASMs for adjunct treatment for LGS include:
- Cannabidiol (Epidiolex) (See CBD page.)
- Clobazam (Onfi)
- Felbamate (Felbatol)
- Fenfluramine (Fintepla)
- Lamotrigine (Lamictal)
- Rufinamide (Bazel)
- Topiramate (Topamax)
- Although commonly used, the following agents are not FDA-approved for LGS:
- Levetiracetam (Keppra)
- Brivaracetam (Briviact)
- Zonisamide (Zonegran)
- Lacosamide (Vimpat)
- Ethosuximide (Zarontin)
- Perampanel (Fycompa)
Non-Pharmacological
Non-pharmacological treatment options for drug-resistant epilepsy (DRE), which is defined as failure to achieve sustained seizure freedom after adequate trials of 2 tolerated and appropriately chosen antiseizure medications, are often indicated. [Kwan: 2010]
- Diet therapy
- Ketogenic Diet
- Modified Atkins diet
- Neurostimulation devices [Thirunavu: 2021]
- Vagus nerve stimulation (VNS)
- Deep brain stimulation (DBS)
- Responsive neurostimulation (RNS)
- Implantable closed-loop neurostimulation device with electrodes targeting the bilateral centromedian nucleus of the thalamus
- Palliative surgical intervention [Thirunavu: 2021]
- Corpus callosotomy to disconnect the 2 hemispheres of the brain, can be specifically beneficial for treatment of atonic seizures
Family
New and emerging treatment trials for LGS can be found at Clinical Trials for Children and Adolescents with Lennox-Gastaut Syndrome (clinicaltrials.gov). Support for families can be found at Caregiver Support (LGS Foundation) and Sibling Support (LGS Foundation).
Services and Referrals
Pediatric Neurology
(see NM providers
[5])
Children with LGS should typically be under the care of a pediatric neurologist
with expertise in seizures. If possible, a pediatric epileptologist or epilepsy
center is preferred. If LGS is suspected by a primary care provider, early
referral to a pediatric neurologist is highly recommended.
Early Intervention for Children with Disabilities/Delays
(see NM providers
[34])
Refer
early. Research shows that early discovery, diagnosis, and treatment of children
with developmental delays or disabilities leads to better outcomes in
developmental skills, academic performance, and social skills.
Resources
Information & Support
Related Portal Content
The Medical Home Portal provides information about some
specific seizure syndromes and general diagnostic and management
information, including:
- Seizures/Epilepsy
- Childhood Absence Epilepsy
- Infantile Spasms
- Juvenile Myoclonic Epilepsy (JME)
- Lennox-Gastaut Syndrome
- Childhood Epilepsy with Centrotemporal Spikes (CECTS)
- Febrile Seizures
- Epilepsy Surgery
- Evaluation & Treatment of a First Unprovoked Seizure
- Tapering Antiepileptic Medication
- Ketogenic Diet
- SUDEP (Sudden Death with Epilepsy)
- Seizures & Epilepsy
- Childhood Absence Epilepsy (FAQ)
- Infantile Spasms (FAQ)
- Safety Precautions for Children with Seizures
Information & Support
For Parents and Patients
LGS Foundation
Causes, treatment, and support information for those affected by Lennox-Gastaut syndrome.
Lennox Gastaut Syndrome (Epilepsy Foundation)
Information about who develops this syndrome, what types of seizures it causes, how it affects families, and treatment.
Danny Did Foundation
Its mission is to prevent deaths caused by seizures and advancing public awareness of Sudden Unexpected Death in Epilepsy
(SUDEP).
Practice Guidelines
Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A.
Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations.
Front Neurol.
2017;8:505.
PubMed abstract / Full Text
Services for Patients & Families in New Mexico (NM)
Service Categories | # of providers* in: | NM | NW | Other states (3) (show) | | NV | RI | UT |
---|---|---|---|---|---|---|---|---|
Early Intervention for Children with Disabilities/Delays | 34 | 3 | 30 | 13 | 51 | |||
Pediatric Neurology | 5 | 5 | 18 | 8 |
For services not listed above, browse our Services categories or search our database.
* number of provider listings may vary by how states categorize services, whether providers are listed by organization or individual, how services are organized in the state, and other factors; Nationwide (NW) providers are generally limited to web-based services, provider locator services, and organizations that serve children from across the nation.
Helpful Articles
PubMed search for articles on Lennox Gastaut Syndrome in children for the last 3 years.
Nelson JA, Knupp KG.
Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions.
Neurotherapeutics.
2023;20(5):1255-1262.
PubMed abstract / Full Text
Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, Genton P, Guerrini R, Kluger G, Pellock JM, Perucca E, Wheless
JW.
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.
Lancet Neurol.
2009;8(1):82-93.
PubMed abstract
Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D.
Treatment of pediatric epilepsy: European expert opinion, 2007.
Epileptic Disord.
2007;9(4):353-412.
PubMed abstract
Authors & Reviewers
Author: | Shanna Swartwood, MD |
Page Bibliography
Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, Genton P, Guerrini R, Kluger G, Pellock JM, Perucca E, Wheless
JW.
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.
Lancet Neurol.
2009;8(1):82-93.
PubMed abstract
Asadi-Pooya AA.
Lennox-Gastaut syndrome: a comprehensive review.
Neurol Sci.
2018;39(3):403-414.
PubMed abstract
Bourgeois BF, Douglass LM, Sankar R.
Lennox-Gastaut syndrome: a consensus approach to differential diagnosis.
Epilepsia.
2014;55 Suppl 4:4-9.
PubMed abstract
Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A.
Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations.
Front Neurol.
2017;8:505.
PubMed abstract / Full Text
Cross JH, Benítez A, Roth J, Andrews JS, Shah D, Butcher E, Jones A, Sullivan J.
A comprehensive systematic literature review of the burden of illness of Lennox-Gastaut syndrome on patients, caregivers,
and society.
Epilepsia.
2024.
PubMed abstract
Gidal B, Detyniecki K.
Rescue therapies for seizure clusters: Pharmacology and target of treatments.
Epilepsia.
2022;63 Suppl 1(Suppl 1):S34-S44.
PubMed abstract / Full Text
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J.
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.
Epilepsia.
2010;51(6):1069-77.
PubMed abstract
Nelson JA, Knupp KG.
Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions.
Neurotherapeutics.
2023;20(5):1255-1262.
PubMed abstract / Full Text
Patel AD, Becker DA.
Introduction to use of an acute seizure action plan for seizure clusters and guidance for implementation.
Epilepsia.
2022;63 Suppl 1:S25-S33.
PubMed abstract
Sullivan J, Benítez A, Roth J, Andrews JS, Shah D, Butcher E, Jones A, Cross JH.
A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: Prevalence, incidence,
diagnosis, and mortality.
Epilepsia.
2024.
PubMed abstract
Thirunavu V, Du R, Wu JY, Berg AT, Lam SK.
The role of surgery in the management of Lennox-Gastaut syndrome: A systematic review and meta-analysis of the clinical evidence.
Epilepsia.
2021;62(4):888-907.
PubMed abstract
Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D.
Treatment of pediatric epilepsy: European expert opinion, 2007.
Epileptic Disord.
2007;9(4):353-412.
PubMed abstract
Zhou P, He N, Zhang JW, Lin ZJ, Wang J, Yan LM, Meng H, Tang B, Li BM, Liu XR, Shi YW, Zhai QX, Yi YH, Liao WP.
Novel mutations and phenotypes of epilepsy-associated genes in epileptic encephalopathies.
Genes Brain Behav.
2018;17(8):e12456.
PubMed abstract